BLTE vs SRRK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BLTE · Belite Bio$127.38 ▼ 15.65%
SRRK · Scholar Rock$48.13 ▼ 4.45%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BLTE -6.3%
- SRRK +15.2%
Head to head
| Metric | BLTE | SRRK |
|---|---|---|
| Price | $127.38 | $48.13 |
| Change today | ▼ 15.65% | ▼ 4.45% |
| Market cap | $5.17B | $5.87B |
| Return, 3 months | -19.8% | -17.3% |
| Return, year to date | -20.4% | +9.3% |
| Return, 1 year | +5.7% | +19.7% |
| P/E (TTM) | – | – |
| P/B | 6.7 | 34.8 |
| P/E percentile vs own 5y | 40th | 26th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -39.6% | -4.9% |
| Gross margin | – | 98.6% |
| Operating margin | – | -71,732.3% |
| Net margin | – | -72,563.2% |
| Return on equity | -21.2% | -200.0% |
| Analyst target vs. price | +81.9% | +46.9% |
| Analyst buy share | 100% | 88% |
| RSI (14) | 32 | 56 |
| 30-day volatility | 74.4% | 59.6% |
| Max drawdown, 1 year | -34.2% | -34.0% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SRRK is the largest of the group by market value.
- SRRK has returned the most over the past year.
- SRRK has been the calmest stock over the last 30 days.